The literature availabletoday regarding the application of molecules acting on the endocannabinoid system for ALS treatment converges in the possible evaluation of a therapy based on CB2 selective agonists.A three-dimensional representation of both CB1 and CB2 receptorsis provided in Figure 21. This evidence concerns the gene CNR1 and amyotrophic lateral sclerosis.